ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly zepbound (tirzepatide — Obesity & obstructive sleep apnea) — Worldwide revenue ($M) ($M)
Form 10-Q / 10-K Note 2, MD&A & Form 8-K Earnings Releases
Latest, Q2 2026
4,928
Period ended Jun 30, 2026
Change on a year earlier
+45.8%
3,381 in Q2 2025
History
14 quarters
Since Q1 2023
Sources
11
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up zepbound (tirzepatide — obesity & obstructive sleep apnea) — worldwide revenue ($m)
Cite this data
StockData. (2026). Eli Lilly Zepbound (tirzepatide — Obesity & obstructive sleep apnea) — Worldwide revenue ($M) ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_zepbound_ww
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.